The World Health Organization has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting the continued spread of A (H3N2) subclade K and growing circulation of new B/Victoria lineage strains. In response, Sino Biological has launched a comprehensive panel of antigens for these strains to accelerate influenza vaccine development.
Since its identification in August 2025, H3N2 subclade K has become the dominant influenza A strain worldwide. Defined by the T135K and S144N mutations, this strain exhibits enhanced immune escape, prompting WHO's selection of A/Darwin/1454/2025 as the new H3N2 reference viruses. The H1N1 component has been updated to A/Missouri/11/2025. Alongside H3N2, influenza B activity is rising sharply, with the proportion of B/Victoria lineage viruses recently increasing from 6% to over 20% in regions such as Hong Kong and the U.S. These trends led WHO to recommend B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains for the upcoming season.
To support global influenza vaccine research and development, Sino Biological has launched an extensive portfolio of recombinant antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains, spanning key viral antigens including Hemagglutinin, Neuraminidase, and Nucleoprotein. These include H1N1 reagents for A/Missouri/11/2025, H3N2 subclade K proteins aligned with A/Darwin/1454/2025, and influenza B reagents in development for the recommended strains. The company provides stable HA trimers with high purity and SEC-MALS validation that maintain native conformation for accurate immune characterization.
Dr. Rob Burgess, Chief Business Officer at Sino Biological US, stated that the company's mission is to provide the scientific community with the highest quality tools as rapidly as possible when infectious disease evolution threatens global health preparedness. The availability of these antigens enables researchers to begin vaccine development immediately rather than waiting for traditional methods of antigen production, potentially shortening the timeline for new vaccine formulations. This rapid response capability is particularly important given the enhanced immune escape properties of the H3N2 subclade K strain and the increasing prevalence of influenza B viruses.
The implications of this announcement extend across the global health landscape. Vaccine manufacturers and research institutions now have access to standardized, high-quality reagents that can facilitate more efficient vaccine development processes. This acceleration could lead to more timely availability of effective vaccines against the evolving influenza strains, potentially reducing the public health impact of the upcoming flu season. The development addresses a critical need in pandemic preparedness, as influenza viruses continue to evolve with mutations that enhance their ability to evade existing immunity. For more information about Sino Biological's products and services, visit https://www.sinobiological.com.
